{"id":20209,"date":"2019-12-20T11:48:07","date_gmt":"2019-12-20T11:48:07","guid":{"rendered":"https:\/\/traders-paradise.com\/magazine\/?p=20209"},"modified":"2020-07-07T16:12:24","modified_gmt":"2020-07-07T15:12:24","slug":"roche-got-european-commissions-approval-for-kadcyla","status":"publish","type":"post","link":"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/","title":{"rendered":"Roche Got European Commission&#8217;s Approval For Kadcyla"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_74 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><ul class='ez-toc-list-level-4' ><li class='ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#Kadcyla_is_medicine_for_the_adjuvant_treatment_of_people_with_HER2-positive_early_breast_cancer_with_the_residual_invasive_disease_after_neoadjuvant_treatment_Roche_stock_price_rose_for_more_than_21_over_the_past_12_months\" >Kadcyla is medicine for the adjuvant treatment of people with HER2-positive early breast cancer with the residual invasive disease after neoadjuvant treatment. \nRoche stock price rose for more than 21% over the past 12 months<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#Learn_more_about_breast_cancer\" >Learn more about breast cancer<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#Roche_stock\" >Roche stock<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#About_the_company\" >About the company<\/a><\/li><\/ul><\/nav><\/div>\n<h4><span class=\"ez-toc-section\" id=\"Kadcyla_is_medicine_for_the_adjuvant_treatment_of_people_with_HER2-positive_early_breast_cancer_with_the_residual_invasive_disease_after_neoadjuvant_treatment_Roche_stock_price_rose_for_more_than_21_over_the_past_12_months\"><\/span><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-20210 size-full\" src=\"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/roche-top-1.jpg\" alt=\"Roche Got European Commission's Approval For Kadcyla\" width=\"800\" height=\"533\" srcset=\"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/roche-top-1.jpg 800w, https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/roche-top-1-300x200.jpg 300w, https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/roche-top-1-768x512.jpg 768w, https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/roche-top-1-370x247.jpg 370w, https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/roche-top-1-760x506.jpg 760w, https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/roche-top-1-424x282.jpg 424w\" sizes=\"auto, (max-width: 800px) 100vw, 800px\" \/><br \/>\n<strong>Kadcyla is medicine for the adjuvant treatment of people with HER2-positive early breast cancer with the residual invasive disease after neoadjuvant treatment.<br \/>\nRoche stock price rose for more than 21% over the past 12 months<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p><span style=\"font-weight: 400;\">Roche on December 19 has announced that the European Commission has approved Kadcyla for the after-surgical treatment of patients with HER2-positive early phase breast cancer. Kadcyla is a single agent for treatment HER2-positive patients metastatic breast or lymph nodes cancer.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">According to Levi Garraway, Roche\u2019s Chief Medical Officer and Head of Global Product Development, this approval of Kadcyla from the European Commission &#8220;will allow many more women with HER2-positive early breast cancer to be given a transformative treatment that may cut the risk of their disease returning or progressing.&#8221;<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The purpose of neoadjuvant treatment is to make tumors smaller thus enhances surgical results. Adjuvant treatment helps to eliminate any residual cancer cells and reduce the risk of cancer returning. Patients who have the remaining disease after neoadjuvant treatment have a worse prognosis and this drug should help them to improve the chances of longer and normal life.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The good results of treatment with Kadcyla are well-known in the US where women are already been treated with this drug. The US Food and Drug Administration approved this treatment on May 4 this year. Kadcyla is approved in 27 countries for the treatment of early breast cancer phase. It is recommended by the St. Gallen International Breast Cancer Conference, the NCCN and the AGO.<\/span><\/p>\n<h4><span class=\"ez-toc-section\" id=\"Learn_more_about_breast_cancer\"><\/span><strong>Learn more about breast cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n<p><a href=\"https:\/\/www.breastcancer.org\/\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-20212 size-full\" src=\"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/roche-s-1.jpg\" alt=\"\" width=\"800\" height=\"533\" srcset=\"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/roche-s-1.jpg 800w, https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/roche-s-1-300x200.jpg 300w, https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/roche-s-1-768x512.jpg 768w, https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/roche-s-1-370x247.jpg 370w, https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/roche-s-1-760x506.jpg 760w, https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/roche-s-1-424x282.jpg 424w\" sizes=\"auto, (max-width: 800px) 100vw, 800px\" \/><\/a><\/p>\n<h3><span class=\"ez-toc-section\" id=\"Roche_stock\"><\/span><b>Roche stock<\/b><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Roche stock price (SIX: RO, ROG; OTCQX: RHHBY) has risen more than 21% over the past 12 months. During that time, Roche Holding AG got two approvals of new treatments for breast cancer. Kadcyla and Perjeta, both came from the large oncology drugs portfolio at Roche&#8217;s Genentech group.<\/span><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-20211 size-full\" src=\"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/Roche-chart-1.jpg\" alt=\"Roche stock price chart\" width=\"800\" height=\"382\" srcset=\"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/Roche-chart-1.jpg 800w, https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/Roche-chart-1-300x143.jpg 300w, https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/Roche-chart-1-768x367.jpg 768w, https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/Roche-chart-1-370x177.jpg 370w, https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/Roche-chart-1-760x363.jpg 760w, https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/Roche-chart-1-424x202.jpg 424w\" sizes=\"auto, (max-width: 800px) 100vw, 800px\" \/><\/p>\n<p><span style=\"font-weight: 400;\">So, Roche Holding AG&#8217;s stock price is higher than it was 12 months ago, with a return of about 6.4% in the same period. Moreover, it looks like it can hold up for the long-term. <a href=\"https:\/\/traders-paradise.com\/magazine\/2019\/10\/european-undervalued-stocks\/\">For investors<\/a>, it may seem like very good news. But, the long-term returns were 17% over the three years. It wasn&#8217;t too much.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">And Roche Holding had a Total Shareholder Return (TSR) of 25% for the last year. That beat its share price return. This is mainly a result of its dividend payments!\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Roche Holding has paid shareholders with a TSR of 25% in the past twelve months. The dividend is included. As we can see the TSR for one year is better than for 3 years, which means that the Roche stock is running better in the more recent period.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The share price momentum continues strong, and it might be worth paying attention to this stock. <\/span><span style=\"font-weight: 400;\">At the time of writing (December 20), the price of Roche (RHHB) stock is $39.38 and data shows that the asset price is in an uptrend for the past 12 months with a further rising trend. That may drive the price up to $46 or $47 in the next 12 months.\u00a0<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The current consensus among analysts is to buy stock in Roche Holding AG.<\/span><\/p>\n<h3><span class=\"ez-toc-section\" id=\"About_the_company\"><\/span><b>About the company<\/b><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Roche is a pharmaceutical and diagnostics company, the largest biotech company in the world. This combination under the roof of one company made it the leader in personalized healthcare.<br \/>\n<\/span><span style=\"font-weight: 400;\">Its products are aimed at oncology, infectious diseases, immunology, ophthalmology and diseases of the CNS. Roche is famous for in-vitro diagnostics and tissue-based cancer diagnostics. Also, it is a leader in diabetes treatments.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">The company is founded in 1896. Since then, more than thirty drugs developed by Roche are in the World Health Organization Model Lists of Essential Medicines.<br \/>\n<\/span><span style=\"font-weight: 400;\">By the Dow Jones Sustainability Indices (DJSI), Roche is for 11 years one of the most sustainable companies in the pharmaceutical industry.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Its headquarters is in Basel, Switzerland. Last year, Roche invested around $11.2 billion in R&amp;D and posted sales of almost $58 billion. In the US, Genentech is a wholly-owned member of the Roche Group. Also, Roche is the majority shareholder in Chugai Pharmaceutical, Japan.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kadcyla is medicine for the adjuvant treatment of people with HER2-positive early breast cancer with the residual invasive disease after neoadjuvant treatment. Roche stock price rose for more than 21% over the past 12 months Roche on December 19 has announced that the European Commission has approved Kadcyla for the after-surgical treatment of patients with [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":20213,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[1004,1006],"tags":[1495,1494,1492,1493],"class_list":["post-20209","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-financial-news","category-top-stocks-for-buy-and-hold","tag-breast-cancer","tag-kadcyla","tag-roche","tag-roche-stock"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Roche Got Approval For Kadcyla - Traders-Paradise<\/title>\n<meta name=\"description\" content=\"Roche got the European Commission&#039;s approval for Kadcyla, a drug for the adjuvant treatment of people with HER2-positive early breast cancer &gt;&gt; READ MORE\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche Got Approval For Kadcyla - Traders-Paradise\" \/>\n<meta property=\"og:description\" content=\"Roche got the European Commission&#039;s approval for Kadcyla, a drug for the adjuvant treatment of people with HER2-positive early breast cancer &gt;&gt; READ MORE\" \/>\n<meta property=\"og:url\" content=\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/\" \/>\n<meta property=\"og:site_name\" content=\"Traders-Paradise\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TradersParadisecom\" \/>\n<meta property=\"article:published_time\" content=\"2019-12-20T11:48:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-07-07T15:12:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/Roche-f-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1100\" \/>\n\t<meta property=\"og:image:height\" content=\"572\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Editor\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Traders_Paradis\" \/>\n<meta name=\"twitter:site\" content=\"@Traders_Paradis\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Editor\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/\"},\"author\":{\"name\":\"Editor\",\"@id\":\"https:\/\/traders-paradise.com\/magazine\/#\/schema\/person\/ce94bb3c5a52307ca7be58f0e7b93ffe\"},\"headline\":\"Roche Got European Commission&#8217;s Approval For Kadcyla\",\"datePublished\":\"2019-12-20T11:48:07+00:00\",\"dateModified\":\"2020-07-07T15:12:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/\"},\"wordCount\":670,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/traders-paradise.com\/magazine\/#organization\"},\"image\":{\"@id\":\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/Roche-f-1.png\",\"keywords\":[\"breast cancer\",\"Kadcyla\",\"Roche\",\"Roche stock\"],\"articleSection\":[\"Financial News\",\"Top Stocks for Buy and Hold\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/\",\"url\":\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/\",\"name\":\"Roche Got Approval For Kadcyla - Traders-Paradise\",\"isPartOf\":{\"@id\":\"https:\/\/traders-paradise.com\/magazine\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/Roche-f-1.png\",\"datePublished\":\"2019-12-20T11:48:07+00:00\",\"dateModified\":\"2020-07-07T15:12:24+00:00\",\"description\":\"Roche got the European Commission's approval for Kadcyla, a drug for the adjuvant treatment of people with HER2-positive early breast cancer >> READ MORE\",\"breadcrumb\":{\"@id\":\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#primaryimage\",\"url\":\"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/Roche-f-1.png\",\"contentUrl\":\"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/Roche-f-1.png\",\"width\":1100,\"height\":572},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/traders-paradise.com\/magazine\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche Got European Commission&#8217;s Approval For Kadcyla\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/traders-paradise.com\/magazine\/#website\",\"url\":\"https:\/\/traders-paradise.com\/magazine\/\",\"name\":\"Traders-Paradise\",\"description\":\"Talking Algo Trader\",\"publisher\":{\"@id\":\"https:\/\/traders-paradise.com\/magazine\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/traders-paradise.com\/magazine\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/traders-paradise.com\/magazine\/#organization\",\"name\":\"Traders-Paradise\",\"url\":\"https:\/\/traders-paradise.com\/magazine\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/traders-paradise.com\/magazine\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/07\/cropped-TP-Full-Landscape-transparent.png\",\"contentUrl\":\"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/07\/cropped-TP-Full-Landscape-transparent.png\",\"width\":3816,\"height\":1402,\"caption\":\"Traders-Paradise\"},\"image\":{\"@id\":\"https:\/\/traders-paradise.com\/magazine\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/TradersParadisecom\",\"https:\/\/x.com\/Traders_Paradis\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/traders-paradise.com\/magazine\/#\/schema\/person\/ce94bb3c5a52307ca7be58f0e7b93ffe\",\"name\":\"Editor\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/traders-paradise.com\/magazine\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bb0ccf0e7e25a4fa2fdbb8a41db860a35a9a574a1d7bb9f62b566ee95074f611?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bb0ccf0e7e25a4fa2fdbb8a41db860a35a9a574a1d7bb9f62b566ee95074f611?s=96&d=mm&r=g\",\"caption\":\"Editor\"},\"url\":\"https:\/\/traders-paradise.com\/magazine\/author\/gorica\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Roche Got Approval For Kadcyla - Traders-Paradise","description":"Roche got the European Commission's approval for Kadcyla, a drug for the adjuvant treatment of people with HER2-positive early breast cancer >> READ MORE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/","og_locale":"en_GB","og_type":"article","og_title":"Roche Got Approval For Kadcyla - Traders-Paradise","og_description":"Roche got the European Commission's approval for Kadcyla, a drug for the adjuvant treatment of people with HER2-positive early breast cancer >> READ MORE","og_url":"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/","og_site_name":"Traders-Paradise","article_publisher":"https:\/\/www.facebook.com\/TradersParadisecom","article_published_time":"2019-12-20T11:48:07+00:00","article_modified_time":"2020-07-07T15:12:24+00:00","og_image":[{"width":1100,"height":572,"url":"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/Roche-f-1.png","type":"image\/png"}],"author":"Editor","twitter_card":"summary_large_image","twitter_creator":"@Traders_Paradis","twitter_site":"@Traders_Paradis","twitter_misc":{"Written by":"Editor","Estimated reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#article","isPartOf":{"@id":"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/"},"author":{"name":"Editor","@id":"https:\/\/traders-paradise.com\/magazine\/#\/schema\/person\/ce94bb3c5a52307ca7be58f0e7b93ffe"},"headline":"Roche Got European Commission&#8217;s Approval For Kadcyla","datePublished":"2019-12-20T11:48:07+00:00","dateModified":"2020-07-07T15:12:24+00:00","mainEntityOfPage":{"@id":"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/"},"wordCount":670,"commentCount":0,"publisher":{"@id":"https:\/\/traders-paradise.com\/magazine\/#organization"},"image":{"@id":"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#primaryimage"},"thumbnailUrl":"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/Roche-f-1.png","keywords":["breast cancer","Kadcyla","Roche","Roche stock"],"articleSection":["Financial News","Top Stocks for Buy and Hold"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/","url":"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/","name":"Roche Got Approval For Kadcyla - Traders-Paradise","isPartOf":{"@id":"https:\/\/traders-paradise.com\/magazine\/#website"},"primaryImageOfPage":{"@id":"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#primaryimage"},"image":{"@id":"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#primaryimage"},"thumbnailUrl":"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/Roche-f-1.png","datePublished":"2019-12-20T11:48:07+00:00","dateModified":"2020-07-07T15:12:24+00:00","description":"Roche got the European Commission's approval for Kadcyla, a drug for the adjuvant treatment of people with HER2-positive early breast cancer >> READ MORE","breadcrumb":{"@id":"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#primaryimage","url":"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/Roche-f-1.png","contentUrl":"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/12\/Roche-f-1.png","width":1100,"height":572},{"@type":"BreadcrumbList","@id":"https:\/\/traders-paradise.com\/magazine\/2019\/12\/roche-got-european-commissions-approval-for-kadcyla\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/traders-paradise.com\/magazine\/"},{"@type":"ListItem","position":2,"name":"Roche Got European Commission&#8217;s Approval For Kadcyla"}]},{"@type":"WebSite","@id":"https:\/\/traders-paradise.com\/magazine\/#website","url":"https:\/\/traders-paradise.com\/magazine\/","name":"Traders-Paradise","description":"Talking Algo Trader","publisher":{"@id":"https:\/\/traders-paradise.com\/magazine\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/traders-paradise.com\/magazine\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/traders-paradise.com\/magazine\/#organization","name":"Traders-Paradise","url":"https:\/\/traders-paradise.com\/magazine\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/traders-paradise.com\/magazine\/#\/schema\/logo\/image\/","url":"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/07\/cropped-TP-Full-Landscape-transparent.png","contentUrl":"https:\/\/traders-paradise.com\/magazine\/wp-content\/uploads\/2019\/07\/cropped-TP-Full-Landscape-transparent.png","width":3816,"height":1402,"caption":"Traders-Paradise"},"image":{"@id":"https:\/\/traders-paradise.com\/magazine\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/TradersParadisecom","https:\/\/x.com\/Traders_Paradis"]},{"@type":"Person","@id":"https:\/\/traders-paradise.com\/magazine\/#\/schema\/person\/ce94bb3c5a52307ca7be58f0e7b93ffe","name":"Editor","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/traders-paradise.com\/magazine\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/bb0ccf0e7e25a4fa2fdbb8a41db860a35a9a574a1d7bb9f62b566ee95074f611?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bb0ccf0e7e25a4fa2fdbb8a41db860a35a9a574a1d7bb9f62b566ee95074f611?s=96&d=mm&r=g","caption":"Editor"},"url":"https:\/\/traders-paradise.com\/magazine\/author\/gorica\/"}]}},"_links":{"self":[{"href":"https:\/\/traders-paradise.com\/magazine\/wp-json\/wp\/v2\/posts\/20209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/traders-paradise.com\/magazine\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/traders-paradise.com\/magazine\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/traders-paradise.com\/magazine\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/traders-paradise.com\/magazine\/wp-json\/wp\/v2\/comments?post=20209"}],"version-history":[{"count":3,"href":"https:\/\/traders-paradise.com\/magazine\/wp-json\/wp\/v2\/posts\/20209\/revisions"}],"predecessor-version":[{"id":23232,"href":"https:\/\/traders-paradise.com\/magazine\/wp-json\/wp\/v2\/posts\/20209\/revisions\/23232"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/traders-paradise.com\/magazine\/wp-json\/wp\/v2\/media\/20213"}],"wp:attachment":[{"href":"https:\/\/traders-paradise.com\/magazine\/wp-json\/wp\/v2\/media?parent=20209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/traders-paradise.com\/magazine\/wp-json\/wp\/v2\/categories?post=20209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/traders-paradise.com\/magazine\/wp-json\/wp\/v2\/tags?post=20209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}